Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label, Phase I Clinical Trial to Assess the Immunogenicity and Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects

NCT02111070 is registered in ClinicalTrials.gov with Il-Yang Pharm. Co., Ltd. as lead sponsor.

NCT NCT02111070
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02111070 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label, Phase I Clinical Trial to Assess the Immunogenicity and Safety of the 'IL-YANG Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects
Lead sponsor
Il-Yang Pharm. Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2012
Completion date
October 31, 2012
Enrollment
44 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy